Compare Carvana Co (CVNA) vs Eli Lilly And Co (LLY) Price & Performance

Carvana (CVNA) trades at $74.20, up 4.73% today, with strong recent earnings beats and bullish technical signals. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, while net income reached a record $513 million. The stock faces valuation concerns with a P/E of 38.1 and EV/EBITDA of 575.03, but positive cash flow trends and analyst consensus support growth prospects.

The outlook remains optimistic due to robust unit growth and AI-driven cost efficiencies, though risks include profit margin compression and high debt levels. With a consensus price target of $87.18, upside potential exists if execution continues, but investors should monitor competitive pressures and macroeconomic headwinds.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.